IORIO, Anna Maria
 Distribuzione geografica
Continente #
NA - Nord America 1.751
EU - Europa 1.313
AS - Asia 654
SA - Sud America 2
AF - Africa 1
Totale 3.721
Nazione #
US - Stati Uniti d'America 1.733
IE - Irlanda 377
UA - Ucraina 368
HK - Hong Kong 178
VN - Vietnam 157
SG - Singapore 150
IT - Italia 115
FI - Finlandia 103
SE - Svezia 94
CN - Cina 87
DE - Germania 85
RU - Federazione Russa 64
TR - Turchia 38
KR - Corea 29
GB - Regno Unito 28
BE - Belgio 23
CA - Canada 13
FR - Francia 12
CH - Svizzera 10
NL - Olanda 8
LB - Libano 7
UZ - Uzbekistan 7
AT - Austria 5
GR - Grecia 5
MX - Messico 5
PL - Polonia 5
CZ - Repubblica Ceca 4
RO - Romania 4
BR - Brasile 2
ES - Italia 2
GH - Ghana 1
IN - India 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.721
Città #
Chandler 383
Dublin 377
Jacksonville 214
San Mateo 181
Hong Kong 178
Dong Ket 157
Singapore 117
Boardman 98
Ann Arbor 93
Medford 77
Princeton 77
Wilmington 55
Andover 48
Izmir 38
Beijing 37
Perugia 29
Ashburn 27
Helsinki 27
Des Moines 24
Saint Petersburg 21
Brussels 20
Altamura 17
Genoa 17
Munich 16
Norwalk 15
Woodbridge 15
Dongjak-gu 14
Seoul 13
Ottawa 12
Lawrence 10
Redwood City 10
Los Angeles 9
Houston 8
Shanghai 7
Redmond 6
Falls Church 5
Auburn Hills 4
Den Haag 4
Corciano 3
Dearborn 3
Heusden 3
Milan 3
Moscow 3
Sona 3
Terni 3
Amsterdam 2
Cuernavaca 2
Dallas 2
Faenza 2
Fortaleza 2
Frankfurt Am Main 2
Madrid 2
New York 2
Philadelphia 2
Pistoia 2
Sacheon-si 2
Timisoara 2
Turin 2
Andra 1
Augusta 1
Bratislava 1
Bucharest 1
Como 1
Costa Mesa 1
Florence 1
Hangzhou 1
Hanover 1
Lenzburg 1
Messina 1
Mexico 1
Miami 1
Muenster 1
Nanchang 1
Olomouc 1
Rome 1
Romola 1
San Jose 1
San Paolo di Civitate 1
Sandston 1
Santa Clara 1
Seattle 1
Solon 1
St Petersburg 1
Stockholm 1
Tempio Pausania 1
Toronto 1
Vienna 1
Warsaw 1
Totale 2.537
Nome #
"Immunogenicity of the MF-59-adjuvanted influenza vaccine in volunteers of different groups of age" 4th National Congress of the Italian Society of Virology (SIV) 89
Antibody response and protection after intradermal and intramuscular 2011/2012 trivalent influenza vaccination in elderly volunteers 89
" MF-59-adjuvanted influenza vaccine: immunogenicity and protection in adult and elderly volunteers (winter season 2003/2004)" 85
An influenza A/H3N2 outbreak during the 2004/05 winter in elderly vaccinated people living in a nursing home 84
Immunogenicità ed efficacia protettiva del vaccino influenzale per l’inverno 2007/08 in soggetti anziani residenti in casa di riposo” 36° Congresso Nazionale della Società Italiana di Microbiologia 81
Antibody Responses after Influenza Vaccination in Elderly People: Useful Information from a 27-Year Study (from 1988–1989 to 2014–2015) 80
I benefici della vaccinazione influenzale Analisi e prospettive nella popolazione non anziana a rischio 79
Effect of age on serum heterologous antibody response elicited by inactivated influenza virus vaccine” 7th National Congress of the Italian Society of Virology 78
Annually repeated influenza vaccination and humoral response in elderly volunteers. 74
Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59 adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. 69
An influenza A/H3 outbreak during the 2004/05 winter in elderly vaccinated people living in a nursing home. 68
An influenza B outbreak in elderly vaccinated people in the winter season 2007/2008” The Third European Influenza Conference 66
[Colony inhibition test (C.I.T.) and the cytotoxic adherence test (C.A.T.): some comparative data]. 65
Immunogenicity of the MF-59-adjuvanted influenza vaccine in volunteers of different groups of age. 64
An influenza A/H3 outbreak during the 2004/2005 winter in elderlyvaccinated people living in a nursing home 63
Influenza vaccine immunogenicity and efficacy in istitutionalized elderly volunteers (winter season 2002/03). 60
Antibody response against unchanged influenza vaccine components in elderly people vaccinated in consecutive years 60
Proceedings of the X National Biotechnology Congress. 59
An observational retrospective study provide information on hospitalization and severe outcomes of the 2009 A(H1N1) infection in Italy. 59
A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60–85 years old) and very elderly (>85 years old) institutionalized subjects 59
Induzione di risposta immunitaria e di protezione da parte dei vaccini antinfluenzali in soggetti anziani. 58
Differente risposta anticorpale al vaccine anti-influenzale per l’inverno 2008/2009 in soggetti anziani residenti in due differenti case di riposo. 58
Antibody response elicited by 2012/2013 “implemented influenza vaccines”, FLUAD® (Novartis Vaccines & Diagnostics) and INTANZA® 15Mcg (Sanofi Pasteur MSD), in chronically ill institutionalized elderly volunteers 58
Influenza vaccination in patients on long-term anticoagulant therapy 58
Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages 57
Interaction Between Influenza Vaccination and Oral Anticoagulant Therapy: A Randomized Blinded Clinical Trial. 57
Influenza B virus circulation in elderly vaccinated people living in a nursing home in the winter season 2007/2008” 8th National Congress of the Italian Society of Virology 55
[Natural resistance and induced resistance to ATPC + tumor in mice]. 54
Influenza vaccine induced antibody response against B influenza viruses included in the vaccine or naturally circulating during the winter season 2010/2011 54
Immunogenicity of conventional trivalent inactivated influenza vaccines in pre-vaccination unprotected elderly volunteers in five winters seasons. 53
Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers. 53
Immunobiological aspects of the nude mouse model relative to human cancer chemosensitivity tests. 53
Pandemic Influenza A/H1N1pdm in Italy: Age, Risk and Population Susceptibility 53
The effect of influenza vaccination in patients on long-term oral anticoagulant therapy 52
An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. 50
Induction of cross-reactive antibodies to 2009 pandemic H1N1 influenza virus (pH1N1) after seasonal vaccination (winters 2003/04 and 2007/08). 49
Comparative study on immunogenicity among split, intradermal and MF59-adjuvanted influenza vaccines in elderly institutionalized subjects 48
Hospitalization associated with 2009 pandemic influenza A(H1N1) infection in Umbria, a region of central Italy, July – December 2009. 47
Induction of Cross-Reactive Antibodies to 2009 Pandemic H1N1 Influenza Virus (pH1N1) After Seasonal Vaccination (Winters 2003/04 and 2007/08) 47
MF-59-adjuvanted influenza vaccine: immunogenicity and protection in adult and enderly volunteers (winter season 2003/04). 46
Clinical characteristics of influenza A/H1N1, A/H3N2 and B infections in children during three consecutive winter seasons (2012-13, 2013-14 and 2014-15) 46
Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. 46
Synthesis and immuno-characterization of HSV-1 peptides for a potential vaccine 45
Cross-reactive antibodies to viruses of both B/Victoria and B/Yamagata lineages as induced by influenza vaccination in middle-aged and elderly volunteers 45
Radioresistant Inhibition of Tumors (RIT): Biological and Pharmacological Studies 45
Pro-inflammatory cytokines/ chemokines production after infection of A549 Human epithelial cell line with different strains of human influenza viruses 45
Immunization with adjuvanted and non-adjuvanted influenza vaccines of HIV-1 positive patients treated with highly active antiretroviral therapy (HAART) 44
Immunogenicity of the MF-59-adjuvanted vaccine in volunteers of different group of age. 44
[The serum protein picture in mice with ATPC ascites tumors studied by means of disk electrophoresis]. 44
The intersubunit region of influenza virus haemagglutinin as a peptide vaccine candidate. 44
Partial Protection Induced by 2011–2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People 44
Declined antibody response following influenza vaccination in elderly as compared with middle-aged volunteers: effects of aging and/or original antigenic sin? 42
Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. 40
Seroprevalence against pandemic influenza A(H1N1) 2009 after the first season of circulation in Italy 40
Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. 39
Influenza vaccine induction of cross–reactive antibodies against different B/Yamagata and B/Victoria-like influenza viruses. , 39
VALUTAZIONE DELL’EFFICACIA PROTETTIVA E DELLA CAPACITA’ DI INDURRE ANTICORPI CROSS-REATTIVI NEI CONFRONTI DI VIRUS INFLUENZALI DI TIPO B APPARTENENTI AI LINEAGGI YAMAGATA E VICTORIA DA PARTE DI DUE VACCINI INFLUENZALI TRIVALENTI (FLUAD® E INTANZA®) IN ANZIANI ISTITUZIONALIZZATI 39
Comparative study of immunogenicity of split, intradermal and MF59-adjuvanted influenza vaccines in elderly institutionalized subjects 38
[Selective inhibition of the response to the allograft of a virus in mice] 38
Increased immunogenicity of an adjuvanted influenza vaccine compared with a conventional subunit vaccine in non-elderly adult HIV seropositive individuals, treated with HAART 36
Sorveglianza delle paralisi flaccide acute nella regione Umbria 36
Intradermal and intramuscular 2011-2012 influenza vaccination of elderly institutionalized volunteers: induction of antibody responses against vaccine and epidemic influenza virus strains 35
Twenty-seven years experience with immunogenicity of inactivated influenza vaccines in the elderly 35
Serologically diagnosed influenza virus A/California/7/04 (H3N2)infection in people immunised with A/Fujan/411/2002(H3N2)antigen during the 2004/05 winter season 34
Influenza A virus specific T cell immunity in humans during ageing 34
Seroprevalence to the 2009 pandemic influenza a(H1N1) virus in the italian population after the 2009 pandemic (September/November 2010) 34
Soggetti ricoverati in ospedale in Umbria con diagnosi di laboratorio di infezione da virus influenzale pandemico A/H1N1 nel periodo Luglio 2009 - Marzo 2010 34
Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review 34
Laboratory confirmed pandemic H1N1 influenza virus infections in hospitalization in Umbria, a region of central Italy (May-November 2009). 33
Induzione di anticorpi omologhi e cross-reattivi nei confronti di virus influenzali di tipo B da parte del vaccino influenzale nell'inverno 2003/2004 32
Influenza vaccination in patients on long-term anticoagulant therapy 32
The new pandemic A/H1N1 influenza virus (pH1N1): celluler and humoral cross-reactive immune responses induced in healthy adults following 2007/2008 influenza vaccination. 31
Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus 29
Sorveglianza molecolare delle gastroenteriti da rotavirus in Umbria 26
Factors influencing humoral immune response after influenza vaccination in elderly and very elderly subjects 25
ENDOGENOUS INTERLEUKYN-6 LEVELS AND ANTIBODY RESPONSE TO INACTIVATED INFLUENZA VACCINE IN PLURIVACCINATED ELDERLY VOLUNTEERS 24
Serological evidence of partial protection against infection with A/H3N2 circulating drifted strains after immunization with enhanced 2011/2012 trivalent influenza vaccines 18
Totale 3.860
Categoria #
all - tutte 15.920
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.920


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020264 0 0 0 0 54 3 57 17 60 35 9 29
2020/2021751 14 57 10 61 207 23 74 3 65 14 61 162
2021/2022581 11 109 4 14 26 6 6 211 5 23 76 90
2022/20231.113 89 109 20 93 88 119 0 63 484 3 35 10
2023/2024483 32 45 30 9 3 1 125 28 71 4 86 49
2024/2025223 15 114 31 59 4 0 0 0 0 0 0 0
Totale 3.860